Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL1007230 | 1.00 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Tetrahydrofuran SCHEMBL3544589 | 0.98 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Tetrahydrofuran SCHEMBL2014438 | 0.95 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Tetrahydrofuran SCHEMBL28244884 | 0.89 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Tetrahydrofuran SCHEMBL28163050 | 0.89 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Tetrahydrofuran SCHEMBL28244765 | 0.89 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Dioxane SCHEMBL27471817 | 0.87 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2LMNA | |
| Oxirane SCHEMBL29388114 | 0.85 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2LMNA | |
| Tetrahydrofuran SCHEMBL28355034 | 0.79 | ALDH1A1 (0.36) | CYP3A4TDP1ALDH1A1LMNASMN1; SMN2 | |
| Cyclohexane SCHEMBL28199422 | 0.79 | CYP3A4 (0.80) | CYP3A4TDP1ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124772-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY USING THE SAME, RING-OPENING METATHESIS POLYMER OBTAINABLE WITH THE METATHESIS CATALYST, AND PROCESS FOR PRODUCING THE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1950216-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY THE PROCESS, METATHESIS POLYMER FORMED BY RING OPENING POLYMERIZATION WITH THE SAME, AND PROCESS FOR PRODUCING POLYMER WITH THE SAME | Mitsui Chemicals, Inc. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124772-A1 | PROCESS FOR PRODUCING ORGANIC TRANSITION METAL COMPLEX COMPOUND, METATHESIS CATALYST PRODUCED BY USING THE SAME, RING-OPENING METATHESIS POLYMER OBTAINABLE WITH THE METATHESIS CATALYST, AND PROCESS FOR PRODUCING THE POLYMER | PORCN, ICMT, ME1 | CYP3A4 672/4885TDP1 4360/4885ESR1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.